✉news BusinessLabor first seen 7 h ago, last 7 h ago, peak #29
Forge and TECPR2 Foundation Partner on AAV Gene Therapy
Original: Forge, TECPR2 Research Foundation Strike AAV Gene Therapy Development, Manufacturing Partnership
Forge Biologics and the TECPR2 Research Foundation have announced a partnership covering the development and manufacturing of AAV-based gene therapy, aimed at advancing potential treatments for TECPR2-related genetic disorders. The deal combines Forge's manufacturing capabilities with the foundation's research focus, and observers in the biotech industry are watching it as a further example of nonprofits teaming up with contract manufacturers to accelerate rare-disease therapy programs.
Why now: The new partnership announcement is fresh news of interest to the gene therapy and rare-disease community.
Forge BiologicsTECPR2 Research Foundation
Evidence
- Forge, TECPR2 Research Foundation Strike AAV Gene Therapy Development, Manufacturing Partnership · Contract Pharma
API: https://socialmediatrends-api.osmike.com/v1/trends/420416